|
|
|
|
ALL
Hallböök H, Gustafsson G, Smedmyr B, Söderhäll S, Heyman M; Swedish Adult Acute Lymphocytic
Leukemia Group; Swedish Childhood Leukemia Group. Treatment outcome in young adults and children >10 years of age with
acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006 Oct 1;
107(7): 1551-61.
Hallböök H, Hägglund H, Stockelberg D, Nilsson PG, Karlsson K, Björkholm M, Linderholm M, Wahlin A, Linder O, Smedmyr B;
Swedish Adult ALL Group. Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group
experience. Bone Marrow Transplant 2005 Jun; 35(12): 1141-8.
Hallböök H, Simonsson B, Ahlgren T, et al. High-dose cytarabine in upfront therapy for adult patients with acute
lymfoblastic leukemia. Br J Haematol 2002; 118 (3): 748-754.
Åström M, Bodin L and Tidefelt. Adjustment of incidence rates after an estimate of completeness and accuracy in
registration of acute leukemias in a swedish population. Leukemia and Lymphoma 2001; 41 (5-6): 559-570.
AML
Juliusson G, Antunovic P, Derolf Å, Lehmann S, Möllgård L, Stockelberg D, Tidefelt U, Wahlin A, Höglund M. Age and
acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood
2009 Apr 30; 113(18): 4179-4187.
Läs artikeln här.
Juliusson G, Billström R, Gruber A, Hellström-Lindberg E, Höglund M, Karlsson K, Stockelberg D, Wahlin A, Aström M,
Arnesson C, Brunell-Abrahamsson U, Carstensen J, Fredriksson E, Holmberg E, Nordenskjöld K, Wiklund F; Swedish Adult Acute
Leukemia Registry Group. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences
survival. Leukemia 2006 Jan; 20(1): 42-7.
Åström M, Bodin L and Tidefelt. Adjustment of incidence rates after an estimate of completeness and accuracy in
registration of acute leukemias in a swedish population. Leukemia and Lymphoma 2001; 41 (5-6): 559-570.
Åström M, Bodin L, Nilsson I and Tidefelt U. Treatment, long-term outcome and prognostic variables in 214 unselected
AML patients in Sweden. British Journal of Cancer 2000; 82 (8): 1387-1392.
Bröstcancer
Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast Cancer in Young
Women: Poor Survival Despite Intensive Treatment. PLoS ONE 2009; 4(11): e7695. doi:10.1371/journal.pone.0007695.
För att läsa hela artikeln klicka här!
Lambe M, Wigertz A, Holmqvist M, Adolfsson J, Bardage C, Fornander T, Karlsson P, Odlind V, Persson I, Ahlgren J,
Bergkvist L. Reductions in use of hormone replace-ment therapy: effects on Swedish breast cancer incidence trends only seen
after several years. Breast Cancer Res Treat. 2009 Nov 6. [Epub ahead of print].
Ahlin C, Zhou W, Holmqvist M, Holmberg L, Nilsson C, Jirström K, Blomqvist C, Amini R-M, Fjällskog M-L. Cyclin A Is a
Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer. Cancer Epidemiol Biomarkers Prev September
2009; 18(9).
Eaker S, Halmin M, Bellocco R, Bergkvist L, Ahlgren J, Holmberg L, Lambe M; on behalf of the Uppsala/Örebro Breast
Cancer Group. Social differences in breast cancer survival in relation to patient management within a National Health Care
System (Sweden). Int J Cancer 2008 Oct 9. [Epub ahead of print].
Läs mer här!
Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE,
Peralta O, Arriagada R, Holmqvist M, Maenpaa J; HABITS Study Group. Increased risk of recurrence after hormone replacement
therapy in breast cancer survivors. J Natl Cancer Inst. 2008 Apr 2; 100(7): 475-82.
Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, Karlsson P, Anderson H, Emdin S. Absolute risk
reductions for local recurrence after postope-ative radiotherapy after sector resection for ductal carcinoma in situ of the
breast. J Clin Oncol. 2008 Mar 10; 26(8): 1247-52.
Bergkvist L, de Boniface J, Jönsson PE, Ingvar C, Liljegren G, Frisell J; on behalf of the Swedish Breast Cancer Group;
Swedish Society of Breast Surgeons. Axillary Recurrence Rate After Negative Sentinel Node Biopsy in Breast Cancer:
Three-Year Follow-Up of the Swedish Multicenter Cohort Study. Ann Surg. 2008 Jan; 247(1): 150-156.
Ahlin C, Guhne B, Holmqvist M, Zetterberg A, Fjällskog M-L. Aberrant expression of cyclin E in low-risk node negative
breast cancer. Acta Oncologica 2008; 1-7.
Schüle J, Frisell J, Ingvar C, Bergkvist L. Sentinel node biopsy for breast cancer larger than 3 cm in diameter.
Br J Surg. 2007 Aug; 94(8): 948-51.
Villman K, Ohd JF, Lidbrink E, Malmberg L, Lindh B, Blomqvist C, Nordgren H, Bergh J, Bergström D, Ahlgren J.A phase II
study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast
cancer. Eur J Cancer 2007 May; 43(7): 1153-60.
Celebioglu F, Frisell J, Danielsson R, Bergkvist L. Sentinel node biopsy in non-palpable
breast cancer and in patients with a previous diagnostic excision. Eur J Surg Oncol 2007 Apr; 33(3): 276-80.
Ringberg A, Nordgren H, Thorstensson S, Idvall I, Garmo H, Granstrand B, Arnesson LG, Sandelin K, Wallgren A, Anderson
H, Emdin S, Holmberg L. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for
ductal carcinoma in situ of the breast – results from the Swedish randomized trial. Eur J Cancer 2007; 43: 291-298.
Dalberg K, Eriksson J, Holmberg L. Birth outcome in women with previously treated breast cancer - A population-based
cohort study from Sweden. PLoS Medicine, Sept 2006; 3(9): e336.
Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A. SweDCIS:
Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered
mammography screening. Acta Oncol 2006; 45: 536-543.
Holmberg L. Allmän mammografi minskar dödlighet i bröstcancer. Onkologi i Sverige 2006; (3): 46-48.
Koinberg IL, Langius-Eklöf A, Holmberg L, Fridlund B. The usefulness of a multidisciplinary educational programme after breast cancer
surgery: A prospective and comparative study. Eur J Oncol Nurs 2006 Feb 10 [Epub ahead of print].
The Swedish Organised Service Screening Evaluation Group (1,2), (L Holmberg Chair of Management Committee). Reduction in breast cancer
mortality from organised service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev
2006; 15: 45-51.
The Swedish Organised Service Screening Evaluation Group (1,2), (L Holmberg Chair of Management Committee). Reduction in breast cancer
mortality from organised service screening with mammography: 2. Validation with alternative analytic methods. Cancer Epidemiol Biomarkers
Prev 2006; 15: 52-56.
Eaker S, Dickman PW, Bergkvist L, Holmberg L. Differences in Management of Older Women Influence Breast Cancer Survival: Results from a
Population-Based Database in Sweden. PLoS Med 2006 Jan 17; 3(3): e25.
Läs artikeln här.
Eaker S, Dickman PW, Hellstrom V, Zack MM, Ahlgren J, Holmberg L. Regional differences in breast cancer survival despite common guidelines.
Cancer Epidemiol Biomarkers Prev 2005 Dec; 14(12): 2914-8.
Läs artikeln här.
Pawitan Y, Bjöhle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A,
Sandelin K, Shaw PM, Smeds J, Skoog L, Wedrén S, Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant
therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005; 7: R953-R964. Epub 2005 Oct. 3.
Lagerlund M, Bellocco R, Karlsson P, Tejler G, Lambe M. Socio-economic factors and breast cancer survival - a population-based cohort study
(Sweden). Cancer Causes and Control 2005; 16: 419-430.
Smeds J, Wärnberg F, Norberg T, Nordgren H, Holmberg L, Bergh J. Ductal carcinoma in situ of the breast with different histopathological
grades and corresponding new breast tumour events: Analysis of loss of heterozygosity. Acta Oncol 2005; 44: 41-49.
Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, Carlsson G, Ohd J, Rudenstam CM, Gustavsson B, Bergh J. Worse survival
for TP53 (p53) -mutated breast cancer patients receiving adjuvant CMF. Ann Oncol 2005; 16: 743-748.
Nilsson G, Holmberg L, Garmo H, Terent A, Blomqvist C. Increased incidence of stroke in women with breast cancer. Eur J Cancer 2005; 41:
423-429.
Bergkvist L, Liljegren G, Ahlgren J, Lidin A, Holmqvist M, Holmberg L. Register bidrar till bättre bröstcancervård. Läkartidningen 2004;
101(34): 2579-81.
Holmberg L. Studie om hormonersättningsbehanling hos kvinnor med tidigare bröstcancer avbruten. Läkartidningen 2004; 101: 2467.
Koinberg IL, Fridlund B, Engholm GB, Holmberg L. Nurse-led follow-up on demand or by a physician after breast cancer surgery: a randomised
study. Eur J Oncol Nurs 2004; 8: 109-117.
Eskelinen M, Nordén T, Lindgren A, Wide L, Adami HO, Holmberg L. Preoperative serum levels of follicle stimulating hormone (FSH) and
prognosis in invasive breast cancer. Eur J Surg Oncol 2004; 30: 495-500.
Holmberg L, Anderson H. Stopping HABITS. Lancet 2004; 363: 1476-7.
Holmberg L, Anderson H; HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer – is it
safe?), randomised comparison: trial stopped. Lancet 2004; 363: 453-5.
Lindahl T, Landberg G, Ahlgren J, Nordgren J, Norberg T, Klaar S, Holmberg L, Bergh J. Overexpression of cyclin E protein is associated
with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 2004; 25: 375-380.
Holmberg L, von Schoultz E, Mattsson LÅ. Unikt samarbete mellan studier om hormonersättningsbehandling efter tidigare bröstcancer.
Läkartidningen 2003; 100: 2317.
Fredriksson I, Liljegren G, Palm-Sjövall M, Arnesson LG, Emdin SO, Fornander T, Lindgren A, Nordgren H, Idvall I, Holmqvist M, Holmberg L,
Frisell J. Risk factors for local recurrence after breast-conserving surgery. Br J Surgery 2003; 90: 1093-1102.
Malmström P, Holmberg L, Anderson H, Mattsson J, Jönsson PE, Tennvall-Nittby L, Balldin G, Lovén L, Svensson JH, Ingvar C, Möller T,
Holmberg E, Wallgren A; Swedish Breast Cancer Group. Breast conservation surgery, with and without radiotherapy, in women with lymph
node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer. 2003; 39:
1690-7.
Ahlgren J, Risberg B, Villman K, Bergh J. Angiogenesis in invasive breast carcinoma--a prospective study of tumour heterogeneity. Eur J
Cancer. 2002 Jan; 38(1): 64-9.
Fredriksson I, Liljegren G, Arnesson L, Emdin S, Palm-Sjövall M, Fornander T, Holmqvist M, Holmberg L, Frisell J. Local recurrence in the
breast after conservative surgery - a study of prognostic factors in 391 women. Eur J Cancer 2002; 38: 1860.
Wärnberg F, Casalini P, Nordgren H, Bergkvist L, Holmberg L, Menard S. Ductal carcinoma in situ of the breast: a new phenotype
classification system and its relation to prognosis. Breast Cancer Res Treat 2002; 73: 215-221
Fredriksson I, Liljegren G, Arnesson LG, Emdin SO, Palm-Sjövall M, Fornander T, Holmqvist M, Holmberg L, Frisell J. Consequences of
axillary recurrence after conservative breast surgery. Br J Surgery 2002; 89: 902-908.
Duffy SW, Tabar L, Chen HH, Holmqvist M, Yen MF, Abdsalah S, Epstein B, Frodis E, Ljungberg E, Hedborg-Melander C, Sundbom A, Tholin M,
Wiege M, Åkerlund A, Wu HM, Tung TS, Chiu YH, Chiu CP, Huang CC, Smith RA, Rosén M, Stenbeck M, Holmberg L. The impact of organized mammography
service screening on breast carcinoma mortality in seven Swedish counties: A collaborative evaluation. Cancer 2002; 95: 458-469.
Ahlgren J, Holmberg L, Bergh J, Liljegren G. Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in
operable breast cancer. Eur J Surg Oncol 2002; 28: 97-102.
Michels KB, Holmberg L, Bergkvist L, Wolk A. Coffee, tea, and caffeine consumption and breast cancer incidence in a cohort of Swedish women.
Ann Epidemiol 2002; 12: 21-26.
Koinberg IL, Holmberg L, Fridlund B. Breast cancer patients’ satisfaction with a spontaneous system of chek-up visits to a specialist nurse.
Scand J Caring Sci 2002; 16: 209-215.
Bergh J, Holmquist Marit. Who should not receive adjuvant chemotherapy? International databases. Journal of the National Cancer
Institute Monographs 2001; No 30, 103-108.
Wärnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br
J Cancer 2001; 85: 869-874.
Wärnberg F, Bergh J, Zack M, Holmberg L. Risk factors for subsequent invasive breast cancer and beast cancer death after ductal carcinoma
in situ. A population-based case-control study in Sweden. Cancer Epid Biomark Prev 2001; 10: 495-499.
Norberg T, Klaar S, Kärf G, Nordgren H, Holmberg L, Bergh J. Increased p53 mutation frequency during tumor progression – results from a
breast cancer cohort. Cancer Res 2001, 61: 8317-21.
Michels KB, Holmberg L, Bergkvist L, Ljung H, Bruce Å, Wolk A. Dietary antioxidant vitamins, retinol, and breast cancer incidence in a
cohort of Swedish women. Int J Cancer 2001; 91: 563-567.
Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J. The expression of vascular endothelial growth factor
correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001, 61: 2256-60.
Fredriksson I, Liljegren G, Arnesson L-G, Emdin SO, Palm-Sjövall M, Fornander T, Frisell J, Holmberg L. Time trends in the results of
breast conservation in 4694 women. Eur J Cancer 2001; 37: 1537-1544.
Koinberg IL, Holmberg L, Fridlund B. Satisfaction with routine follow-up visits to the physician: The needs of patients with breast cancer.
Acta Oncol 2001; 40: 454-459.
Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast cancer: A case control study from Scandinavia. Acta
Oncol 2001; 40: 467-471.
Holmberg L, Nordén T, Lindgren A, Wide L, Degerman M, Adami HO. Pre-operative oestradiol levels - relation to survival in breast cancer.
Eur J Surg Oncol 2001; 27: 152-156.
Wärnberg F, Yuen J, Holmberg L. Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 2000; 355: 724-25.
Hjärntumörer
Danfors T, Ribom D, Ghaderi Berntsson S, Smits A. Epileptic seizures and survival during early disease in grade 2
gliomas. Eur J Neurol 2009; 16:, 823-31.
Lindberg N, Kastemar M, Olofsson T, Smits A, Uhrbom L. Oligodendrocyte progenitor cells can act as cell of origin for
experimental glioma. Oncogene 2009; 28: 2266-2275.
Smits A, Westerberg E, Ribom D. Adding 11C-methionine PET to EORTCs prognostic factors in grade 2 gliomas.
Eur J Nucl Med 2008; 1: 65-71.
Hagerstrand D, Smits A, Eriksson A, Sigurdardottir S, Olofsson T, Nistér M, Kalimo H, Östman A. Gene expression
analyses of grade II gliomas and identification of rPTP beta/zeta as a candidate oligodendroglioma marker. Neuro-oncol
2008; 1:, 2-9.
Qu M, Olofsson T, Sigurdardottir S, Kalimo H, Nistér M, Smits A, Ren Z-P. Genetically distinct astrocytic and
oligodendroglial components in oligoastrocytoma. Acta Neuropathol 2007; 113: 129-136.
Ren Z-P, Olofsson T, Qu M, Hesselager G, Soussi T, Kalimo H, Smits A, Nistér M. Molecular genetic analysis of p53
intratumoral heterogeneity in human astrocytic tumors. J Neuropathol Exp Neurol 2007; 66: 944-954.
A. Granat, G. Ahlström, A. Smits. Ett nytt integrerat omhändertagande av patienter med gliom. Ett
vårdutvecklingsprojekt hos Cancerfonden 2000-2002, Slutrapport.
Bergenheim T, Malmström A, Bolander H, Michanek A, Stragliotto G, Damber L, Björ O, Henriksson R. Registrering av primära
hjärntumörer mått på nationell vårdkvalitet. Regionala skillnader avslöjade. Läkartidningen 2007; 104(5): 332-341.
Läs artikeln här!
Hardell LO, Carlberg M, Soderqvist F, Hansson Mild K, Morgan LL. Long-term use of cellular phones and brain tumours -
increased risk associated with use for > 10 years. Occup Environ Med. 2007 Apr 4; [Epub ahead of print].
Hardell L, Carlberg M, Hansson Mild K. Pooled analysis of two Swedish case-control studies on the use of mobile and
cordless telephones and the risk of brain tumours diagnosed during 1997-2003. Int J Occup Saf Ergon. 2007; 13(1): 63-71.
Hardell L, Hansson Mild K, Carlberg M, Soderqvist F. Tumour risk associated with use of cellular telephones or cordless
desktop telephones. World J Surg Oncol. 2006 Oct 11; 4: 74.
Hardell L, Carlberg M, Mild KH. Case-control study of the association between the use of cellular and cordless
telephones and malignant brain tumors diagnosed during 2000-2003. 2006 Feb; 100(2): 232-41. Epub 2005 Jul 14.
Ribom D, Schoenmaekers M, Engler H, Smits A. Evaluation of 11C-methionine PET as a surrogate endpoint after
treatment of grade 2 gliomas. J Neuro-oncol 2005; 71: 325-332.
Ribom D and Smits A. Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas.
Neurol Res 2005; 27: 516-21.
Ek L, Smits A, Påhlson A, Almqvist O. Analysis of cognitive dysfunction in patients with low-grade glioma. J Clin Psych
in Med 2005. Settings 12, 165-173.
Hardell L, Eriksson M, Carlberg M, Sundstrom C, Hansson Mild K. Use of cellular or cordless telephones and the risk for
non-Hodgkin's lymphoma. Int Arch Occup Environ Health. 2005 Sep; 78(8): 625-32. Epub 2005 Oct 12.
Hardell L, Carlberg M, Hansson Mild K. Case-control study on cellular and cordless telephones and the risk for acoustic
neuroma or meningioma in patients diagnosed 2000-2003. Neuroepidemiology. 2005; 25(3):120-8. Epub 2005 Jun 13.
Hardell L, Hansson Mild K, Carlberg M, Hallquist A. Cellular and cordless telephone use and the association with brain
tumors in different age groups. Arch Environ Health. 2004 Mar; 59(3): 132-7.
Ribom D, Smits A, Hartman M, Persson L, Blomquist E. On the issue of early and aggressive treatment in grade 2 gliomas.
J Cancer Res Clin Oncol 2003; 129: 154-160.
Ribom D, Westman-Brinkmalm A, Smits A, Davidsson P. Alpha-2-HS-glycoprotein in CSF of low-grade gliomas. Identification
by preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionisation-time of flight-mass
spectrometry. Tumor Biol 2003; 24: 94-99.
Ribom D, Larsson A, Pietras K, Smits A. Identification of growth factors (VEGF, PDGF and bFGF) in the CSF of patients
with low-grade gliomas. Neurol Sci 2003; 24: 70-73.
Påhlson A, Ek L, Ahlström G, Smits A. Pitfalls in the assessment of disability in individuals with low-grade gliomas.
J Neuro-oncol 2003; 65: 149-158.
Ribom D, Engler H, Blomquist E, Smits A. Potential significance of 11C-methionine PET as a marker for the
radiosensitivity of low-grade gliomas. Eur J Nucl Med 2002; 29: 632-640.
Ribom D, Andrae J, Friedlingsdorf M, Hartman M, Nistér M, Smits A. Prognostic value of PDGF alpha-receptor expression
in grade 2 astrocytomas and oligoastrocytomas grade 2. J Neurol Neurosurg Psych 2002; 72: 782-787.
Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Långström B, Bolander H, Bergström M, Smits A. Positron Emission
Tomography 11C-methionine and survival in patients with low-grade gliomas. Cancer 2001; 92: 1541-1549.
Smits A, Ribom D. Risk of increased malignancy a reason for
follow-up of low grade glioma. Early identification of high-risk patients is the key to good care. Läkartidningen 2000; 97:
3886-3890.
Ribom D, Adner J, Eriksson A, Persson L, Smits A. Low-grade glioma in the Uppsala/Orebro region. Prognostic factors and
survival among 119 patients. Läkartidningen 2000; 97: 3880-3884.
Huvud/halscancer
Reizenstein J A, Bergström S N, Holmberg L, Linder A, Ekman S, Blomquist E,
Lödén B, Holmqvist M, Hellström K, Nilsson C O, Brattström D, Bergqvist M. Impact of age at diagnosis on prognosis and
treatment in laryngeal cancer. Published online in Wiley InterScience (www.interscience.wiley.com).
HEAD & NECK DOI: 10.1002/hed.21292.
Läs hela artikeln här!
KML
Olsson-Stromberg U, Hoglund M, Bjorkholm M, Braide I, Carlson K, Gahrton G, Grimfors G, Hast R, Lerner R, Linder O,
Ljungman P, Lofvenberg E, Malm C, Nilsson PG, Paul C, Rodjer S, Stenke L, Tidefeldt U, Turesson I, Uden AM, Wahlin A, Vilen
L, Winqvist I, Zettervall O, Oberg G, Simonsson B. Successful mobilization of Ph-negative blood stem cells with intensive
chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma 2006 Sep; 47(9):
1768-73.
Simonsson B, Oberg G, Bjoreman M, Bjorkholm M, Carneskog J, Karlsson K, Gahrton G, Grimfors G, Hast R, Karle H, Linder
O, Ljungman P, Nielsen JL, Nilsson J, Lofvenberg E, Malm C, Olsson K, Olsson-Stromberg U, Paul C, Stenke L, Stentoft J,
Turesson I, Uden AM, Wahlin A, Vilen L, Weis-Bjerrum O. Intensive treatment and stem cell transplantation in chronic
myelogenous leukemia: long-term follow-up. Acta Haematol 2005; 113(3): 155-62.
Olsson-Stromberg U, Simonsson B, Ahlgren T, Bjorkholm M, Carlsson K, Gahrton G, Hast R, Lofvenberg E, Linder O,
Ljungman P, Malm C, Paul C, Rodjer S, Turesson I, Uden AM,
Wahlin A, Killander A, Wadman B, Westin J, Vikrot O, Zettervall O, Oberg G. Comparison of busulphan, hydroxyurea and
allogeneic bone marrow transplantation (BMT) in chronic myeloid leukaemia: BMT prolongs survival. Hematol J 2004; 5(6):
62-6.
Axdorph U, Stenke L, Grimfors G, Carneskog J, Hansen J, Linder O, Ljungman P, Lofvenberg E, Malm C, Simonsson B,
Turesson I, Vilen L, Uden AM, Bjorkholm M. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in
accelerated or blastic phase--a report from the Swedish CML Group. Br J Haematol 2002 Sep; 118(4): 1048-54.
Kolorektalcancer
Jung B, Påhlman L, Johansson R and Nilsson E. Rectal cancer treatment and outcome in the elderly: an audit based on
the Swedish rectal cancer registry 1995–2004. BMC Cancer 2009; 9: 68.
Läs hela artikeln här!
Sorbye H, Pfeiffer P, Wetnzel-Larsen T, Cavalli-Björkman N, Glimelius B. Clinical trial enrollment, patient
characteristics, treatment choices and survival in prospectively registered metastatic colorectal cancer patients. Cancer
2009; 115: 4679-87.
Kodeda K, Holmberg E, Steineck G, Nordgren S. Regional Differences in Local Recurrence Rates after Rectal Cancer
Surgery. Colorectal Dis 2009 Nov 14. [Epub ahead of print].
Gurmu A, Matthiessen P, Nilsson S, Påhlman L, Rutegård J, Gunnarsson U. Is para-stomal hernia a clinical, or a
radiological diagnosis? (Manuscript).
Olsson L, Granström F & Påhlman L. Restorative surgery in rectal cancer is associated with patients´ income.
(Manuscript).
Folkesson J, Ehrnrooth E, Engholm G, Kejs AM, Påhlman L, Wibe A, Tryggvadottir L, Brewster DH, Hakulinen T & Storm
H. Rectal cancer survival in the Nordic countries and Scotland. Int J Cancer
2009; 125: 2406-2412.
Kressner M, Bohe M, Cedermark B, Dahlberg M, Damber L, Lindmark G, Öjerskog B, Sjödahl R, Johansson R, Påhlman L. The
impact of hospital volume on surgical outcome for rectal cancer – a survey of the Swedish Rectal Cancer Register. Dis Colon
Rectum 2009; 52: 1542-1549.
Kressner M, Nilsson P, Johansson R, Glimelius B, Påhlman L. The effect of short-term pre-operative irradiation
on cancer on different levels of the rectum - Local recurrence and survival in. The Swedish Rectal Cancer Register. (Manuscript).
Jörgren F, Johansson R, Damber L, Lindmark G. Risk Factors of Rectal Cancer Local Recurrence: Population-based Survey
and Validation of the Swedish Rectal Cancer Registry. Colorectal Dis 2009 Apr 27. [Epub ahead of print].
Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Late gastrointestinal disorders after rectal cancer surgery with and
without preoperative radiation therapy. Br J Surg 2008; 95: 206-13.
Syk E, Torkzad MR, Blomqvist L, Nilsson PJ, Glimelius B. Local recurrence in rectal cancer: Anatomical localization and
impact on radiation target. Int J Radiat Oncol Biol Phys 2008; 72: 658-64.
van Leeuwen B, Påhlman L, Gunnarsson G, Sjövall A & Martling A. The effect of age and gender on outcome after
surgery for colon carcinoma. A population based study in the Uppsala and Stockholm region. Critical Rev Oncol/Hematol 2008;
67: 229-236.
Jestin P, Påhlman L, Gunnarsson U. Risk factors for anastomotic leakage after rectal cancer surgery: a
case-control study. Colorectal Dis 2008; 10: 715-721.
Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit K, Heikkila R, Keldsen N,
Albertsson M, Starkhammar H, Garmo H, Berglund Å. A randomized phase III multicenter trial comparing irinotecan in
combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2)
in pa-tients with metastatic colorectal cancer. Annals of Oncology 2008; doi: 10.1093/ annonc/mdm588.
Påhlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjödahl R, Öjerskog B, Damber L & Johansson R. The Swedish
Rectal Cancer Registry. Br J Surg 2007; 94: 1285-1292.
Folkesson J, Johansson R, Påhlman L, & Gunnarsson U. Local surgery for rectal cancer – A population based
study. Br J Surg 2007; 94: 1421-1426.
Lennarthson B, Andershed B. Patientens upplevelse av livskvalitet efter kolorektal-kirurgi.
En litteraturstudie. (D-uppsats). Omvårdnadsvetenskap. Hälsovetenskapliga institutionen. Örebro Universitet 2007.
Läs artikeln här.
Engholm G, Kejs AM, Brewster DH, Gaard M, Holmberg L, Hartley R, Iddenden R, Møller H, Sankila R,
Thomson CS, Storm HH. Colorectal cancer survival in the Nordic countries and the United Kingdom: Excess mortality risk analysis
of 5 year relative period survival in the period 1999 to 2000. Int J Cancer 2007; 121: 1115-1122.
Engholm G, Kejs AM, Brewster DH, Gaard M, Holmberg L, Hartley R, Iddenden R, Møller H, Sankila R,
Thomson CS, Storm HH. Colorectal cancer survival in the Nordic countries and the United Kingdom: Excess mortality risk analysis
of 5 year relative period survival in the period 1999 to 2000. Int J Cancer 2007 Apr 23; [Epub ahead
of print].
Jestin P, Påhlman L, Glimelius B & Gunnarsson U. Cancer staging and survival in colon cancer is depending on the
quality of the pathologists’ specimen examination. Eur J Cancer 2005; 41: 2071-2078.
Larsson SC, Rafter J, Holmberg L, Bergkvist L, Wolk A. Red meat consumption and risk of cancers of the proximal colon,
distal colon, and rectum: The Swedish mammography cohort. Int J Cancer 2005; 113: 829-834.
Jestin P, Nilsson J, Heurgren L, Påhlman L, Glimelius B, Gunnarsson U. Emergency surgery for colonic cancer in a defined
population. Br J Surg Januari 2005; 92(1): 94-100.
Folkesson J, Nilsson J, Påhlman L, Glimelius B, Gunnarsson U. The circular stapling device as a risk factor for anastomotic leakage.
Colorectal Dis 2004; 6(4): 275-279.
Jestin P, Heurgren M, Påhlman L, Glimelius B, Gunnarsson U.
Elective surgery for colorectal cancer in a defined Swedish population. Eur J Surg Oncol 2004; 30(1): 26-33.
Cho E, Smith-Warner SA, Ritz J, van der Brandt PA, Colditz GA, Folsom AR, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Holmberg L,
Kim DH, Malila N, Miller AB, Pietinen P, Rohan TE, Sellers TA, Speizer FE, Willett WC, Wolk A, Hunter DJ. Alcohol intake and colorectal cancer:
a pooled analysis of 8 cohort studies. Ann Intern Med 2004; 140: 603-13.
Blom J, Lidén A, Nilsson J, Påhlman L, Nyrén O, Holmberg L. Colorectal cancer screening with flexible sigmoidoscopy – participants´
experiences and technical feasibility. Eur J Surg Oncol 2004; 30: 362-9.
Gunnarsson U. Quality assurance in surgical oncology - Colorectal cancer as an example. Eur J Surg Oncol 2003; 29(1): 89-94.
Gunnarsson U, Seligsohn E, Jestin P, Påhlman L. Registration and validity of surgical complications in colorectal cancer surgery. Br J
Surg April 2003; 90(4): 454-459.
Berglund Å, Molin D, Nordlinder R, Edler D, Graf W, Glimelius B. Thymidylate synthase and p53 expression in primary tumor do not predict
chemotherapy outcome in metastatic colorectal carcinoma. Anticancer Res 2002; 22: 3653-3659.
Jakobsen A, Berglund Å, Glimelius B, Frödin J-E, Hansen F, Kjaer M, Lindegaard Madsen E, Sandberg E, Poulsen JP, Gustavsson B, Carlsson G.
Dose-effect relationship of bolus 5-FU in the treatment of advanced colorectal cancer. A randomized study. Acta Oncol 2002; 41: 525-531.
Dahlberg M, Påhlman L, Glimelius B. Cost-effectiveness of preoperative radiotherapy in rectal cancer. Results from the Swedish Rectal Cancer
Trial. Int J Radiat Oncol Biol Phys 2002; 54: 654-660.
Berglund Å, Molin D, Larsson A, Einarsson R, Glimelius B. Tumour markers as predictors of response to chemotherapy in advanced colorectal
carcinoma. Ann Oncol 2002; 13: 1430-1437.
Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression in
colorectal cancer – a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20:1721-1728.
Köhne C-H, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Arande E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F,
Schöffski P, Micheel S, Hecker H. Clinical determinants of survival in patients with 5-fluorouracil based treatment for metastatic colorectal
cancer. Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308 - 317.
Terry P, Baron JA, Bergkvist L, Holmberg L, Wolk A. Dietary calcium and vitamin D intake and risk of colorectal cancer: a prospective cohort
study in women. Nutr Cancer. 2002; 43: 39-46.
Blom J, Lidén A, Jeppsson B, Holmberg L, Påhlman L. Compliance and findings in a Swedish population screened for colorectal cancer with
sigmoidoscopy. Eur J Surg Oncol. 2002; 28: 827-831.
Terry P, Giovannucci E, Bergkvist L, Holmberg L, Wolk A. Body weight and colorectal cancer risk in a cohort of Swedish women: relation
varies by age and cancer site. Br J Cancer 2001; 85: 346-349.
Terry P, Bergkvist L, Holmberg L, Wolk A. No association between fat and fatty acids intake and risk of colorectal cancer. Cancer Epidemiol
Biomarkers Prev 2001; 10: 913-914.
Terry P, Bergkvist L, Holmberg L, Wolk A. Coffee consumption and risk of colorectal cancer in a population-based prospective cohort of
Swedish women. Gut 2001; 49: 87-90.
Terry P, Giovannucci E, Michels KB, Bergkvist L, Hansen H, Holmberg L, Wolk A. Fruit, vegetables, dietary fiber, and risk of colorectal
cancer. J Natl Cancer Inst 2001; 93: 525-533.
Nordin K, Hoffman K and Glimelius B. Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients.
Br J Cancer 2001; 85: 1265-1272.
Nordin K, Wasteson E, Hoffman K, Glimelius B, Sjödén P-O. Discrepancies between attainment and importance of life values and anxiety and
depression in gastrointestinal cancer patients and their spouses. Psycho-Oncol 2001; 10: 479-489.
Jansson Frykholm G, Påhlman L, Glimelius B. Combined chemo- and radiotherapy vs radiotherapy alone in the treatment of primary,
nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 2001; 50: 427-434.
Bohe M, Cedermark B, Damber L, Lindmark G, Nordgren S, Påhlman L & Sjödahl R. Kvalitetsregister etablerat för
bättre rektalcancerbehandling. Läkartidningen 2000; 97: 3587-3591.
Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colo-rectal cancer: systematic review and meta-analysis.
BMJ 2000; 321: 531-5.
Edler D, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, Påhlman L, Lindmark G, Blomgren H. Immunohistochemically detected
thymidylate synthase in colorectal cancer: An independent prognostic factor of survival. Clin Cancer Res 2000; 6: 488-492.
Lungcancer
Myrdal G, Lamberg K,Lambe M,Ståhle
E,Wagenius G, Holmberg L. Regional differen-ces in treatment and outcome
in non-small cell lung cancer: a population-based study (Sweden). Lung
Cancer. 2009 Jan; 63(1): 16-22.
Wakelee HA, Chang ET, Gomez SL, Keegan THM,
Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK, West
DW. Lung cancer incidence in never smokers. J Clin Oncol 2007; 25:
472-478.Wakelee HA, Chang ET, Gomez SL, Keegan THM, Feskanich D, Clarke
CA, Holmberg L, Yong LC, Kolonel LN, Gould MK, West DW. Lung cancer
incidence in never smokers. J Clin Oncol 2007; 25: 472-478.
Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg
R, Gawande SR. Phase III Trial of Gemcitabine Plus Carboplatin Versus
Single-Agent Gemcitabine in the Treatment of Locally Advanced or
Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study
Group, J Clin Oncol 2005 Nov 20; 23(33): 8380-8.
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon J-P,
Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with
completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:
351-60.
Johan Eriksson. Undersökning av tidstrender i registerdata.
Lungcancerregistret ROC. U.U.D.M. Project Report 2004:3. Mars 2004.
(Examensarbete i matematisk statistik, Matematiska institutionen,
Uppsala Universitet).
Läs
examensarbetet här!
Lymfom
Adde M, Enblad G, Hagberg H, Sundström C,
Laurell A. Outcome for Young High-Risk Aggressive B-Cell Lymphoma
Patients Treated with CHOEP-14 and Rituximab (R-CHOEP-14). Medical
Oncology June 2006; 23(2): 283-294.
Glimelius I, Molin D, Amini R-M, Gustavsson
A, Glimelius B, Enblad G. Bulky disease is the most important prognostic
factor in Hodgkin lymphoma stage IIB. Eur J Haematol 2003; 71: 327-333.
Amini R-M, Enblad G, Engström P, Christensson B, Glimelius B,
Sundström C. Relapsed Hodgkin’s lymphoma: Immunostaining patterns in
relation to survival. Leukemia Lymphoma 2002; 43: 1253-1260.
Amini R-M, Glimelius B, Gustavsson A, Ekman T, Erlanson M,
Haapaniemi E, Enblad G. A population-based study of the outcome for
patients with first relapse of Hodgkin’s lymphoma. Eur J Haematol 2002;
68: 225-232.
Amini R-M, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E
and Glimelius B. Treatment outcome in patients younger than 60 years
with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National
Health Care Programme experience. Eur J Haematol 2000; 65: 379-89.
Malignt melanom
Lindholm C, Andersson R, Dufmats M, Hansson
J, Ingvar C, Möller T, Sjödin H, Stierner U, Wagenius G, for the Swedish
Melanoma Study Group. Invasive cutaneous malignant melanoma in Sweden,
1990-1999. A prospective, population-based study of survival and
prognostic factors. Cancer 2004 Nov 1; 101(9): 2067-2078.
Kanzler MH, Mraz-Gernhard S. Primary cutaneous malignant melanoma
and its precursor lesions: Diagnostic and therapeutic overview. J Am
Acad Dermatol August 2001; 45: 260-276.
Prostatacancer
Holmberg L, Adolfsson J, Mucci L, Garmo H,
Adami HO, Möller H, Johansson JE, Stampfer M. Season of diagnosis and
prognosis in breast and prostate cancer. Cancer Causes Control 2009 Jul;
20(5): 663-70.
Andrèn O, Garmo H, Mucci L,& Andersson S-O, Johansson J-E, Fall K.
Incidence and mortality of incidental prostate cancer: a Swedish
register-based study. Br J Cancer. 2009 Jan 13;100(1):170-3.
Holmström B, Holmberg E, Egevad L, Adolfsson J, Johansson J-E,
Hugosson J, Stattin P. Primary vs. Deferred Radical Prostatectomy in The
National Prostate Cancer Register (NPCR) of Sweden on behalf of the
National Prostate Cancer Register (NPCR) of Sweden. Submitted Nov 200 9.
Stattin P, Holmberg E, Johansson J-E, Holmberg L, Adolfsson J,
Hugosson J. Outcomes for men with localized prostate cancer in the
National Prostate Cancer Register (NPCR) of Sweden. Accepted for
publication JNCI Dec 2009.
Bill-Axelson A, Garmo H, Lambe M, Bratt O, Adolfsson J, Nyberg U,
Steineck G, Stattin P. Suicide Risk in Men with Prostate-Specific
Antigen-Detected Early Prostate Cancer: A Nationwide Population-Based
Cohort Study from PCBaSe Sweden. Eur Urol 2009 Nov 10. [Epub ahead of
print].
Hagel E, Garmo H, Bill-Axelson A, Bratt O, Johansson JE, Adolfsson
J, Lambe M, Stattin P. PCBaSe Sweden: a register-based resource for
prostate cancer research. Scand J Urol Nephrol 2009; 43(5): 342-9.
Carlsson S, Adolfsson J, Bratt O, Johansson JE, Ahlstrand C,
Holmberg E, Stattin P, Hugosson J. Nationwide population-based study on
30-day mortality after radical prostatectomy in Sweden. Scand J Urol
Nephrol 2009; 43(5): 350-6.
Fall K, Strömberg F, Rosell J, Andrèn O, Varenhorst E; South-East
Region Prostate Cancer Group. Reliability of death certificates in
prostate cancer patients. Scand J Urol Nephrol 2008; 42(4): 352-7.
Ladjevardi S, Sandblom G, Berglund A, Varenhorst E. Tumour Grade,
Treatment, and Relative Survival in a Population-based Cohort of Men
with Potentially Curable Prostate Cancer. Eur Urol 2009 Mar 10. [Epub
ahead of print].
Zheng SL, Sun J, Wiklund F, Gao Z, Stattin P, Purcell LD, Adami HO,
Hsu FC, Zhu Y, Adolfsson J, Johansson JE, Turner AR, Adams TS, Liu W,
Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Grönberg H. Genetic
variants and family history predict prostate cancer similar to
prostate-specific antigen Clinical Cancer Research 2009 Feb 1; 15(3):
1105-11.
Liu W, Sun J, Li G, Zhu Y, Zhang S, Kim ST, Sun J, Wiklund F, Wiley
K, Isaacs SD, Stattin P, Xu J, Duggan D, Carpten JD, Isaacs WB, Grönberg
H, Zheng SL, Chang BL. Association of a Germ-Line Copy Number Variation
at 2p24.3 and Risk for Aggressive Prostate Cancer. Cancer Research 2009
Mar 3. [Epub ahead of print]
Lindström S, Adami HO, Bälter K, Xu J, Zheng SL, Sun J, Stattin P,
Grönberg H, Wiklund F. Genetic variation in the upstream region of ERG
and prostate cancer.Cancer Causes Control. 2009 Feb 10.
Wiklund F, Isaacs SD, Stevens VL, Sun J, Smith S, Pruett K, Romero
LM, Wiley KE, Kim ST, Zhu Y, Zhang Z, Hsu FC, Turner AR, Adolfsson J,
Liu W, Kim JW, Duggan D, Carpten J, Zheng SL, Rodriguez C, Isaacs WB,
Gronberg H, Xu J. Fine mapping association study and functional analysis
implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer
risk. Human molecular genetics 2009.
Sun J, Zheng SL, Wiklund F, Isaacs SD, Li G, Wiley KE, Kim ST, Zhu
Y, Zhang Z, Hsu FC, Turner AR, Stattin P, Liu W, Kim JW, Duggan D,
Carpten J, Isaacs W, Gronberg H, Xu J, Chang BL. Sequence variants at
22q13 are associated with prostate cancer risk. Cancer Res 2009;
69:10-5.
Wiklund F, Zheng SL, Sun J, Adami HO, Lilja H, Hsu FC, Stattin P,
Adolfsson J, Cramer SD, Duggan D, Carpten JD, Chang BL, Isaacs WB,
Gronberg H, Xu J. Association of reported prostate cancer risk alleles
with PSA levels among men without a diagnosis of prostate cancer.
Prostate 2009; 69:419-27.
Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C,
Nordling S, Häggman M, Andersson S-O, Bratell S, Spångberg A, Palmgren
J, Adami H-O, Johansson J-E, for the Scandinavian Prostate Cancer Group
Study Number 4. Radical Prostatectomy Versus Watchful Waiting in
Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4
Randomized Trial. JNCI August 20, 2008; 100(16): 1144-1154.
Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu
FC, Zhu Y, Balter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA,
Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Gronberg H. Cumulative
Association of Five Genetic Variants with Prostate Cancer. N Engl J Med
2008 Feb 28; 358(9): 910-9.
Sandblom G, Ladjevardi S, Garmo H, Varenhorst E. The impact of
prostate-specific antigen level at diagnosis on the relative survival of
28,531 men with localized carcinoma of the prostate. Cancer 2008; Feb
15; 112(4): 813-9.
Stattin P, Holmberg E, Bratt O, Adolfsson J, Johansson JE, Hugosson
J. National Prostate Cancer Register. Surveillance and deferred
treatment for localized prostate cancer. Population based study in the
National Prostate Cancer Register of Sweden. J Urol 2008 Dec; 180(6):
2423-9.
Gudmundsson J, et al. Common sequence variants on 2p15 and Xp11.22
confer susceptibility to prostate cancer. Nat Genet 2008; 40: 281-3.
Hsu FC, Lindstrom S, Sun J, Wiklund F, Chen SH, Adami HO, Turner AR,
Liu W, Balter K, Kim JW, Stattin P, Chang BL, Isaacs WB, Xu J, Gronberg
H, Zheng SL. A multigenic approach to evaluating prostate cancer risk in
a systematic replication study. Cancer Genet Cytogenet 2008; 183: 94-8.
Olsson M, Lindström S, Häggkvist B, Adami HO, Bälter K, Stattin P,
Ask B, Rane A, Ekström L, Grönberg H. The UGT2B17 gene deletion is not
associated with prostate cancer risk. Prostate 2008 Apr 1; 68(5): 571-5.
Sun J, Lange EM, Isaacs SD, Liu W, Wiley KE, Lange L, Gronberg H,
Duggan D, Carpten JD, Walsh PC, Xu J, Chang BL, Isaacs WB, Zheng SL.
Chromosome 8q24 risk variants in hereditary and non-hereditary prostate
cancer patients. Prostate 2008 Apr 1; 68(5): 489-97.
Sun J, Purcell L, Gao Z, Isaacs SD, Wiley KE, Hsu FC, Liu W, Duggan
D, Carpten JD, Grönberg H, Xu J, Chang BL, Partin AW, Walsh PC, Isaacs
WB, Zheng SL. Association between sequence variants at 17q12 and 17q24.3
and prostate cancer risk in European and African Americans. Prostate
2008 May 15; 68(7): 691-7.
Sun J, Chang BL, Isaacs SD, Wiley KE, Wiklund F, Stattin P, Duggan
D, Carpten JD, Trock BJ, Partin AW, Walsh PC, Gronberg H, Xu J, Isaacs
WB, Zheng SL. Cumulative effect of five genetic variants on prostate
cancer risk in multiple study populations. Prostate 2008; 68: 1257-62.
Sun J, Zheng SL, Wiklund F, Isaacs SD, Purcell LD, Gao Z, Hsu FC,
Kim ST, Liu W, Zhu Y, Stattin P, Adami HO, Wiley KE, Dimitrov L, Sun J,
Li T, Turner AR, Adams TS, Adolfsson J, Johansson JE, Lowey J, Trock BJ,
Partin AW, Walsh PC, Trent JM, Duggan D, Carpten J, Chang BL, Gronberg
H, Isaacs WB, Xu J. Evidence for two independent prostate cancer
risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008; 40:
1153-5.
Xu J, Isaacs SD, Sun J, Li G, Wiley KE, Zhu Y, Hsu FC, Wiklund F,
Turner AR, Adams TS, Liu W, Trock BJ, Partin AW, Chang B, Walsh PC,
Gronberg H, Isaacs W, Zheng S. Association of prostate cancer risk
variants with clinicopathologic characteristics of the disease. Clin
Cancer Res 2008; 14: 5819-24.
Wiklund F, Lageros YT, Chang E, Balter K, Johansson JE, Adami HO,
Gronberg H. Lifetime total physical activity and prostate cancer risk: a
population-based case-control study in Sweden. Eur J Epidemiol 2008 ;
23(11): 739-46.
Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén
O, Bill-Axelson A, Bratt O, Damber JE, Hellström K, Hellström M,
Holmberg E, Holmberg L, Hugosson J, Johansson JE, Petterson B, Törnblom
M, Widmark A, Stattin P. Clinical characteristics and primary treatment
of prostate cancer in Sweden between 1996 and 2005. Data from the
National Prostate Cancer Register in Sweden. Scand J Urol Nephrol 2007;
41(6): 456-77
McKay JD, Kaaks R, Johansson M, Biessy C, Wiklund F, Balter K, Adami
HO, Boillot C, Gioia-Patricola L, Canzian F, Stattin P, Gronberg H.
Haplotype-based analysis of common variation in the growth hormone
receptor gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev
2007; 16: 169-73.
Johansson M, McKay JD, Stattin P, Canzian F, Boillot C, Wiklund F,
Adami HO, Balter K, Gronberg H, Kaaks R. Comprehensive evaluation of
genetic variation in the IGF1 gene and risk of prostate cancer. Int J
Cancer 2007; 120: 539-42.
Johansson M, Van Guelpen B, Hultdin J, Wiklund F, Adami HO, Balter
K, Gronberg H, Stattin P. The MTHFR 677C T polymorphism and risk of
prostate cancer: results from the CAPS study. Cancer Causes Control
2007; 18: 1169-74.
Johansson M, McKay JD, Wiklund F, Rinaldi S, Verheus M, van Gils CH,
Hallmans G, Balter K, Adami HO, Gronberg H, Stattin P, Kaaks R.
Implications for prostate cancer of insulin-like growth factor-I (igf-I)
genetic variation and circulating igf-I levels. The Journal of clinical
endocrinology and metabolism 2007; 92: 4820-6.
Hedelin M, Chang ET, Wiklund F, Bellocco R, Klint A, Adolfsson J,
Shahedi K, Xu J, Adami HO, Gronberg H, Balter KA. Association of
frequent consumption of fatty fish with prostate cancer risk is modified
by COX-2 polymorphism. Int J Cancer 2007; 120: 398-405.
Torniainen S, Hedelin M, Autio V, Rasinpera H, Balter KA, Klint A,
Bellocco R, Wiklund F, Stattin P, Ikonen T, Tammela TL, Schleutker J,
Gronberg H, Jarvela I. Lactase persistence, dietary intake of milk, and
the risk for prostate cancer in Sweden and Finland. Cancer Epidemiol
Biomarkers Prev 2007; 16: 956-61.
Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F,
Robbins C, Isaacs SD, Cheng Y, Li G, Sun J, Chang BL, Marovich L, Wiley
KE, Balter K, Stattin P, Adami HO, Gielzak M, Yan G, Sauvageot J, Liu W,
Kim JW, Bleecker ER, Meyers DA, Trock BJ, Partin AW, Walsh PC, Isaacs
WB, Gronberg H, Xu J, Carpten JD. Two genome-wide association studies of
aggressive prostate cancer implicate putative prostate tumor suppressor
gene DAB2IP. J Natl Cancer Inst 2007; 99: 1836-44.
Lindstrom S, Adami HO, Balter KA, Xu J, Zheng SL, Stattin P,
Gronberg H, Wiklund F. Inherited variation in hormone-regulating genes
and prostate cancer survival. Clin Cancer Res 2007; 13: 5156-61.
Fall K, Garmo H, Andrén O, Bill-Axelson A, Adolfsson J, Adami HO,
Johansson JE, Holmberg L for the Scandinavian Prostate Cancer Group
Study No 4. Prostate-specific antigen levels as a predictor of lethal
prostate cancer. J Natl Cancer Inst 2007; 99: 526-532.
Amundadottir LT et al. A common variant associated with prostate
cancer in European and African populations. Nat Genet 2006; 38(6):
652-8.
Hedelin M, Klint A, Chang ET, Bellocco R, Johansson JE, Andersson
SO, Heinonen SM, Adlercreutz H, Adami HO, Gronberg H, Balter KA: Dietary
phytoestrogen, serum enterolactone and risk of prostate cancer: the
cancer prostate Sweden study (Sweden). Cancer Causes Control 2006;
17(2): 169-80.
Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J,
Augustsson-Balter K, Chang BL, Adami HO, Liu W, Gronberg H, Xu J.
Genetic variation in the COX-2 gene and the association with prostate
cancer risk. Int J Cancer 2006; 119(3): 668-72.
Sun J, Wiklund F, Hsu FC, Balter K, Zheng SL, Johansson JE, Chang B,
Liu W, Li T, Turner AR, Li L, Li G, Adami HO, Isaacs WB, Xu J, Gronberg
H. Interactions of sequence variants in interleukin-1
receptor-associated kinase4 and the toll-like receptor 6-1-10 gene
cluster increase prostate cancer risk. Cancer Epidemiol Biomarkers Prev
2006; 15(3): 480-5.
Thellenberg-Karlsson C, Lindstrom S, Malmer B, Wiklund F,
Augustsson-Balter K, Adami HO, Stattin P, Nilsson M, Dahlman-Wright K,
Gustafsson JA, Gronberg H: Estrogen receptor beta polymorphism is
associated with prostate cancer risk. Clin Cancer Res 2006; 12(6):
1936-41.
Lindstrom S, Zheng SL, Wiklund F, Jonsson B-A, Adami H-O, Augustsson
Balter K, Brookes AJ, Sun J, Chang B-L, Liu W, Li G, Isaacs WB,
Adolfsson J, Gronberg H, Xu J: Systematic replication study of reported
genetic associations in prostate cancer: Strong support for genetic
variation in the androgen pathway. The Prostate 2006 Dec 1; 66(16):
1729-43.
Lindstrom S, Wiklund F, Adami HO, Balter KA, Adolfsson J,Gronberg H.
Germ-line genetic variation in the key androgen-regulating genes
androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2
is important for prostate cancer development. Cancer Res. 2006 Nov 15;
66(22): 11077-83.
Andersson P, Varenhorst E, Söderkvist P. Androgen receptor and
vitamin D receptor gene polymorphisms and prostate cancer risk. Eur J
Cancer 2006; 42(16): 2833-7.
Sennfält K, Carlsson P, Varenhorst E. Diffusion and economic
consequences of health technologies in prostate cancer care in Sweden
1998-2003. Eur Urol 2006; 49(6): 1028-34.
Holmberg L, Bill-Axelson A, Garmo H, Palmgren J, Norlén BJ, Adami
HO, Johansson JE and the SPCG-4 study group. Prognostic markers under
watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am
2006; 20: 845-855.
Varenhorst E, Garmo H, Holmberg L, Stattin P, Johansson J-E.
Prostatacancer i Sverige 1998-2003. Drastisk förändring av
sjukdomspanoramat. Läkartidningen 2006; 5(103): 285-8. Läs artikeln här.
Lindstrom S, Wiklund F, Jonsson BA, Adami HO, Balter K, Brookes AJ,
Xu J, Zheng SL, Isaacs WB, Adolfsson J, Gronberg H. . Comprehensive
genetic evaluation of common E-cadherin sequence variants and prostate
cancer risk: strong confirmation of functional promoter SNP. Hum Genet
2005; 118(3-4): 339-47.
Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO,
Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami
HO, Norlén BJ, Johansson JE; Scandinavian Prostate Cancer Group Study
No. 4. Radical prostatectomy versus watchful waiting in early prostate
cancer. N Engl J Med 2005; 352; 1977-1984.
Stattin P, Johansson R, Lodnert R, Andren O, Bill-Axelsson A, Bratt
O, et al. Geogra-phical variation in incidence of prostate cancer in
Sweden. Scand J Urol Nephrol 2005; 39(5): 372-9.
Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu FC, et al. The
interaction of four genes in the inflammation pathway significantly
predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005;
14(11 Pt 1): 2563-8.
Lindmark F, Zheng SL, Wiklund F, Balter KA, Sun J, Chang B, et al.
Interleukin-1 receptor antagonist haplotype associated with prostate
cancer risk. Br J Cancer 2005; 93(4): 493-7.
Sun J, Wiklund F, Zheng SL, Chang B, Balter K, Li L, et al. Sequence
variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and
prostate cancer risk. J Natl Cancer Inst 2005; 97(7): 525-32.
Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E. Survival in
prostate carcinoma - outcomes from a prospective, population-based
cohort of 8887 men with up to 15 years of follow-up: results from three
countries in the population-based National Prostate Cancer Registry of
Sweden. Cancer 2005; 103(5): 943-51.
Chang ET, Hedelin M, Adami HO, Gronberg H, Balter KA. Alcohol
drinking and risk of localized versus advanced and sporadic versus
familial prostate cancer in Sweden. Cancer Causes Control 2005; 16(3):
275-84.
Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellström
M, Hugosson J, Lundgren R, Stattin P, Törnblom M, Johansson JE. The
national prostate cancer register in Sweden 1998-2002: Trends in
incidence, treatment and survival. Scand J Urology and Nephrology 2005;
39: 117-123.
Sennfält K. Economic studies of health technology changes in
prostate cancer care. Linköping: Center for Medical Technology
Assessment Department of Healt and Society Linköping University, 2005.
Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L,
Magnuson A, Adami HO. Natural history of early, localized prostate
cancer. JAMA 2004; 291: 2713-2719.
Sandblom G, Varenhorst E. Broadening the criteria for avoiding
staging bone scans in prostate cancer: a retrospective study of patients
at the Royal Marsden Hospital. BJU Int 2004; 93(6): 889-90.
Jonsson BA, Adami HO, Hagglund M, Bergh A, Goransson I, Stattin P,
et al. -160C/A polymorphism in the E-cadherin gene promoter and risk of
hereditary, familial and sporadic prostate cancer. Int J Cancer 2004;
109(3): 348-52.
Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical
consequences of screening for prostate cancer: 15 years follow-up of a
randomised controlled trial in Sweden. Eur Urol 2004; 46(6): 717-23;
discussion 724.
Sennfält K, Sandblom G, Carlsson P, Varenhorst E. Costs and effects
of prostate cancer screening in Sweden - a 15-year follow-up of a
randomized trial. Scand J Urol Nephrol 2004; 38(4): 291-8.
Sennfält K, Carlsson P, Sandblom G, Varenhorst E. The estimated
economic value of the welfare loss due to prostate cancer pain in a
defined population. Acta Oncol 2004; 43(3): 290-6.
Wiklund F, Jonsson BA, Brookes AJ, Stromqvist L, Adolfsson J,
Emanuelsson M, et al. Genetic analysis of the RNASEL gene in hereditary,
familial, and sporadic prostate cancer. Clin Cancer Res 2004; 10(21):
7150-6.
Lindmark F, Zheng SL, Wiklund F, Bensen J, Balter KA, Chang B, et
al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated
with prostate cancer. J Natl Cancer Inst 2004; 96(16): 1248-54.
Lindmark F, Jonsson BA, Bergh A, Stattin P, Zheng SL, Meyers DA, Xu
J, Gronberg H. Analysis of the macrophage scavenger receptor 1 gene in
Swedish hereditary and sporadic prostate cancer. Prostate 2004; 59(2):
132-40.
Sun J, Hedelin M, Zheng SL, Adami HO, Bensen J, Augustsson-Balter K,
et al. Interleukin-6 sequence variants are not associated with prostate
cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13(10): 1677-9.
Sandblom G, Carlsson P, Sennfalt K, Varenhorst E. A population-based
study of pain and quality of life during the year before death in men
with prostate cancer. Br J Cancer 2004; 90(6): 1163-8.
Chang ET, Hedelin M, Adami HO, Gronberg H, Balter KA. Re: Zinc
supplement use and risk of prostate cancer. J Natl Cancer Inst 2004;
96(14): 1108; author reply 1108-9.
Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO,
et al. Sequence variants of toll-like receptor 4 are associated with
prostate cancer risk: results from the CAncer Prostate in Sweden Study.
Cancer Res 2004; 64(8): 2918-22.
Bill-Axelson A, Holmberg L, Norlén BJ, Busch C, Norberg M. No
increased prostate cancer incidence after negative transrectal
ultrasound guided multiple biopsies in men with increased prostate
specific antigen and/or abnormal digital rectal examination. J Urol
2003; 170: 1180-3.
Aus G, Nordenskjold K, Robinson D, Rosell J, Varenhorst E.
Prognostic factors and survival in node-positive (N1) prostate cancer-a
prospective study based on data from a Swedish population-based cohort.
Eur Urol 2003; 43(6): 627-31.
Sennfalt K, Carlsson P, Thorfinn J, Frisk J, Henriksson M,
Varenhorst E. Technological changes in the management of prostate cancer
result in increased healthcare costs--a retrospective study in a defined
Swedish population. Scand J Urol Nephrol 2003; 37(3): 226-31.
Sandblom G, Dufmats M, Olsson M, Varenhorst E. Validity of a
population-based cancer register in Sweden - an assessment of data
reproducibility in the South-East Region Prostate Cancer Register. Scand
J Urol Nephrol 2003; 37(2): 112-9.
Stattin P, Johansson R, Damber JE, Hellstrom M, Hugosson J, Lundgren
R, et al. Non-systematic screening for prostate cancer in Sweden -
survey from the National Prostate Cancer Registry. Scand J Urol Nephrol
2003; 37(6): 461-5.
Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE,
Norlén BJ, Holmberg L. Quality of life after radical prostatectomy or
watchful waiting. N Engl J Med 2002; 347: 790-796.
Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman
M, Andersson SO, Spångberg A, Busch C, Nordling S, Palmgren J, Adami HO,
Johansson JE, Norlén BJ. A randomized trial comparing radical
prostatectomy with watchful waiting in early prostate cancer. N Engl J
Med 2002, 347: 781-789.
Sandblom G, Holmberg L, Damber JE, Hugosson J, Johansson JE,
Lundgren R, Mattsson E, Nilsson J, Varenhorst E. Prostate-specific
antigen as surrogate for characterizing prostate cancer subgroups. Scand
J Urol Nephrol 2002; 36(2): 106-112.
Sandblom G, Holmberg L, Damber JE, Hugosson J, Johansson JE,
Lundgren R, Mattsson E, Nilsson J, Varenhorst E. Prostate-Specific
Antigen for prostate cancer staging in a population-based register.
Scand J Urol Nephrol 2002; 36(2): 99-105.
Egevad L. Reproducibility of Gleason grading of prostate cancer can
be improved by the use of reference images. Urology 2001; 57(2): 291-5.
Sandblom G, Carlsson P, Sigsjo P, Varenhorst E. Pain and
health-related quality of life in a geographically defined population of
men with prostate cancer. Br J Cancer 2001; 85(4): 497-503.
Sandblom G. Diagnosis, management, quality of life, and long-term
survival in prostate cancer patients. Medical Dissertation No 664,
Linköping University, 2001.
Sandblom G, Dufmats M, Nordenskjold K, Varenhorst E. Prostate
carcinoma trends in three counties in Sweden 1987-1996: results from a
population-based national cancer register. South-East Region Prostate
Cancer Group. Cancer 2000; 88(6): 1445-53.
Helgesen F, Andersson SO, Gustafsson O, Varenhorst E, Gobén B,
Carnock S, Sehlstedt L, Carlsson P, Holmberg L, Johansson JE. Follow-up
of prostate cancer patients by on-demand contacts with a specialist
nurse. A randomized study. Scand J Urol Nephrol 2000; 34: 55-61.
Sandblom G, Mattson E, Damber J-E, Johnasson J-E, Lundgren R,
Varenhorst E. Prostate cancer registration in four regions 1996.
Differences in incidence, age structure and management. Scand J Urol
Nephrol. 1999; 33(5): 306-311.
Abstract
Pär Stattin. Mortalitet efter operation, strålning och monitorering
i uppföljningsstudien. Del av symposium om aktiv monitorering, moderator
Ola Bratt. Läkarstämman, November 2008 Göteborg.
Anna Bill Axelsson. Risk för suicid vid prostatacancer. Muntlig
presentation. Läkarstämman November 2008, Göteborg.
Pär Stattin et al. PCBaSe Sweden. Uppföljning och nationella
länkningar ger unik databas för prostatacancerstudier. Poster
Läkarstämman November 2008 Göteborg.
Pär Stattin et al. Surveillance for localized prostate cancer. A
population-based study in the National Prostate Cancer Register (NPCR)
in Sweden. Poster AACR/ASCO, San Francisco Feb 2008.
Sigrid Carlsson et al. Nationell populationsbaserad studie av
perioperativ mortalitet i samband med prostatectomi. Urologisektionen,
Läkarstämman, November Stockholm 2007.
Pär Stattin et al. Duaration av aktiv monitorering/expektans som
primärbehandling av loklaiserad pros-tatacancer. Populationsbaserad
studie i Nationella prostatacancerregis-tret (NPCR). Urologisektionen,
Läkarstämman, November Stockholm 2007.
Jan Adolfsson et al. Nationella prostatacancerregitret – Uppföljning
av kliniska data och primärbehandling 1996-2005. Urologisektionen,
Läkarstämman, November Stockholm 2007.
Stattin P, Holmberg E, Hugosson J. Duration of active monitoring as
primary treatment in localized prostate cancer. A population-based study
of the National prostate cancer register (NPCR) in Sweden. AUA Anaheim,
CA, 2007.
Ladjevardi S, Sandblom G, Garmo H, Varenhorst E. Relativ överlevnad
hos män med potentiellt kurabel prostatacancer. Svenska Läkarsällskapets
Riksstämma, Göteborg, November 2006.
Sandblom G, Löfman O, Rosell J, Ahlstrand C, Robinson D, Hellström
L, Varenhorst E. Geografiska variationer i incidensen av prostatacancer
i Kalmars och Östergötlands Län- en analys med geografiskt
informationssystem (GIS). Svenska Läkarsällskapets Riksstämma, Göteborg,
November 2006.
Sandblom D, Andren O, Fall K, Varenhorst E, Robinson D, Johansson
J-E, Andersson S-O. Betydelse av tumörvolym och Gleasonsumma – en
populationsbaserad uppföljningsstudie av T1 a-b prostatacancer. Svenska
Läkarsällskapets Riksstämma, Göteborg, November 2006.
Hjelmgren J, Sennfält K. Behandling av lokalt avancerad
prostatacancer. Svenska Läkarsällskapets Riksstämma November 2006.
Johansson R, Lodnert R, Andrén O, Stattin P, Bill-Axelsson A, Bratt
O, et al. Stora skillnader i icke-systematisk screening för
prostatacancer i Sverige: Studie från Nationella
prostatacancerregistret. Svenska Läkarsällskapets Riksstämma, November
2004.
Robinson D, Aus G, Rosell J, Sandblom G, Varenhorst E.
Långtidsöverlevnad vid prostatacancer - en populationsbaserad studie.
Svenska Läkarsällskapets Riksstämma, November 2004.
Hugosson J, Bratt O, Damber J-E, Hellström M, Holmberg E, Johansson
J-E, et al. Nationellt Uppföljningsregister för män med lokaliserad
Prostatacancer (PC). Svenska Läkarsällskapets Riksstämma, November 2004.
Robinsson D, Bak J, Gorecki T, Herder A, Rosell J, Varenhorst E.
Sjukdomsspecifik mortalitet och prognostiska faktorer vid prostatacancer
kategori T1a och T1b. Svenska Läkarsällskapets Riksstämma, November
2003.
Stattin P, Johansson R, Damber J-E, Hellström M, Hugosson J,
Lundgren R, et al. Icke-systematisk screening för prostatacancer. Studie
i nationella prostatacancerregistret. Svenska Läkarsällskapets
Riksstämma, November 2003.
Sandblom G, Dufmats M, Olsson M, Varenhorst E. Reproducerbarhet av
data i Sydöstra Regionens Prostatacancerregister. Svenska
Läkaresällskapets Riksstämma, November 2001.
Johansson J-E, Gustavsson O, Hellström M, Holmberg E, Holmberg L,
Hugosson J, Lundgren R, Stattin P, Varenhorst E. Rekordhög
incidensökning av prostatacancer i Sverige under 1999. Rapport från
Nationella Prostatacancerregistret 1996-1999. Svenska Läkaresällskapets
Riksstämma, November 2001.
Pilebro B, Damber J-E, Damber L, Johansson R, Stattin P. Varför togs
PSA-prov som ledde fram till prostatacancerdiagnos? Svenska
Läkaresällskapets Riksstämma, November 2001.
Adolfsson J, Marké L-Å. PSA-användning I Sverige. Svenska
Läkaresällskapets Riksstämma, November 2001.
Johansson J-E, Gustavsson O, Hellström M, Holmberg E, Holmberg L,
Hugosson J, Lundgren R, Stattin P, Varenhorst E. Nationella
prostatacancerregistret 1996-1998. Stora regionala skillnader i incidens
och primärbehandling. Svenska Läkaresällskapets Riksstämma, November
2000.
Johansson J-E. Stora geografiska variationer i incidens och
primärbehandling vid prostatacancer i Sverige. Socialstyrelsens
Kvalitetsregisterdagar, Oktober 2000.
Urinblåsecancer
Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, Malmström PU; Nordic Urothelial Cancer Group. Neoadjuvant cisplatinum
based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004; 45: 297-303.
Sherif A, Rintala E, Mestad O, Nilsson J, Holmberg L, Nilsson S, Malmström PU. Neoadjuvant Cisplatin-methotrexate chemotherapy for invasive
bladder cancer - nordic cystectomy trial 2. Scand J Urol Nephrol 2002; 36: 419-425.
Övriga artiklar
Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register
- a sample survey for year 1998. Acta Oncologica 2008 September 3d, 1-7.
Läs artikeln här!
Skírnisdóttir I, Garmo H, Holmberg L. Non-genital tract metastases to the ovaries presented as
ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer. Gynecol Oncol 2007; 105: 166-71.
Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm Pahl H L, Birgegard G.
Nordic Study Group for Myeloproliferative Disorders. A phase II trial of pegylated interferon α-2b therapy for polycythemia
vera and essential thrombocythemia. Feasibility, clinical and biologic effects, and impact on quality of life. Cancer June 2006; 106 (11):
2397-2405. (Publicerad Online Wiley InterScience 25 april 2006).
Läs abstrakt här.
Holmberg L, Tamini R: Reducing cancer drug doses in obese patients: dogma
dispu-ted. Lancet 2005; 366: 1056-1057.
Zar N, Garmo H, Holmberg L, Rastad J, Hellman P. Long-term survival of patients with small intestinal carcinoid tumours. World J Surg 2004;
28: 1163-1168.
Johansson B, Holmberg L, Berglund G, Sjödén PO, Glimelius B. Determinants of can-cer patients´ utilization of hospital care within two years
after diagnosis. Acta Oncol 2004; 43: 536-544.
Larsson SC, Holmberg L, Wolk A. Fruit and vegetable consumption in relation to ovarian cancer incidence: Swedish Mammography Cohort. Br J
Cancer 2004; 90; 2167-2170.
Pettersson L-M, Berglund G, Brodin O, Glimelius B, Sjödén P-O. A randomised study of the effects of group rehabilitation on quality of life
and psychosocial distress in cancer patients. Psychosoc Med 2003; in press.
Hellbom M, Petersson L-M, Brandberg Y, Berglund G, Holmberg L, Johansson B, Glimelius B, Sjödén P-O. Well-being in conjunction with
diagnosis predicts aspects of cancer pateints’ quality of life one year later. Qual Life Res 2003; in press.
Hallin A, Bergqvist D, Fugl-Meyer K, Holmberg L. Areas of concern, quality of life and life satisfaction in patients with peripheral
vascular disease. Eur J Vasc Endovasc Surg 2002; 24: 255-263.
George M, Wiklund L, Aastrup M, Pousette J, Thunholm B, Saldeen T, Wernroth L, Zarén B, Holmberg L. Incidence and geographical distribution
of sudden infant death syndrome in relation to content of nitrate in drinking water and groundwater levels. Eur J Clin Invest 2001; 31:
1083-1094.
Hallin A, Bergqvist D, Holmberg L. Literature review of surgical management of abdo-minal aortic aneurysm. Eur J Vasc Endovasc Surg 2001;
22: 197-204.
Hellbom M, Brandberg Y, Kurland J, Arving C, Thalén-Lindström A, Glimelius B, Sjödén P-O. Assessment and treatment of psychosocial problems
in cancer patients: an exploratory study of a course for nurses. Pat Educat Couns 2001; 45: 101-106.
Johansson B, Holmberg L, Berglund G, Brandberg Y, Hellbom M, Persson C, Glimelius B, Sjödén P-O. Reduced utilisation of specialist care
among elderly cancer patients: a randomised study of a primary healthcare intervention. Eur J Cancer 2001; 37: 2161-2168.
Nordin K, Berglund G, Glimelius B, Sjödén P-O. Predicting anxiety and depression among cancer patients: a clinical model. Eur J Cancer 2001;
37: 376-84.
Johansson B, Berglund G, Hoffman K, Glimelius B, Sjödén P-O. The role of the gene-ral practitioner in cancer care and the effect of an
extended information routine. Scand J Prim Health Care 2000;18:143-148.
Petersson L, Berglund G, Brodin O, Glimelius B, Sjoden P. Group rehabilitation for cancer patients: satisfaction and perceived benefits.
Patient Educ Couns 2000; 40: 219-229. |
|
